32results about How to "Strong immune protection" patented technology

The invention discloses a Haemonchus contortus nano-material subunit vaccine and applications thereof. The Haemonchus contortus nano-material subunit vaccine is a subunit vaccine prepared by wrappinghaemonchus contortus recombinant protein HCA59 with nano-material PLGA, the recombinant HCA59 protein has an amino acid sequence as shown in SEQ ID NO. 1. The subunit vaccine can be used for preventing haemonchus contortus infection of sheep. The particle size of the nano subunit vaccine is 75 to 402nm; the Haemonchus contortus nano-material subunit vaccine has good biocompatibility and unique physicochemical properties, has the advantages of targeting property, slow release property, safety, high efficiency and the like, and can be decomposed and metabolized in an animal body; the vaccine hasan irritant antigen effect of stimulating dendritic cells, can promote the capability of converting mononuclear cells into the dendritic cells, has relatively strong immunoprotection capability, andcan remarkably reduce the ovum discharge rate and adult reduction rate of goats infected with haemonchus contortus clinically.

The invention belongs to the technical field of gene engineering and tuberculosis vaccine, and provides a recombinant bacillus calmette guerin (BCG) vaccine containing mycobacterium tuberculosis genome RD4 zone related coding genes. According a preparation method, the recombinant bacillus calmette guerin vaccine is produced through transformation of recombinant Escherichia coli-mycobacterium shuttle plasmids containing genes used for coding of mycobacterium tuberculosis genome RD4 zone proteins into bacillus calmette guerin vaccine. The recombinant bacillus calmette guerin vaccine is capable of realizing RD4 zone gene and protein expression. After immunization of animals with the recombinant bacillus calmette guerin vaccine, the safety of recombinant BCG bacterial strain containing complete RD4 zone is not reduced, the safety of recombinant BCG bacterial strain containing a part of RD4 zone (Rv1501-Rv1508c) is increased obviously. The recombinant BCG bacteria strain containing the complete or a part of RD4 zone genes possess better anti-infection protection effects. The recombinant bacillus calmette guerin vaccine can be used in prevention or treatment of tuberculosis.

The invention provides a bovine rotavirus fusion protein and a calf diarrhea polyvalent vaccine, and relates to the technical field of molecular biology. The bovine rotavirus fusion protein contains aVP6 fragment, and the VP6 fragment contains an amino acid sequence as shown in SEQ ID NO.4, wherein at least one loop region in the following (a)-(c) is replaced with an epitope derived from bovine coronavirus and / or an epitope derived from escherichia coli: (a) 168th-177th amino acid residues with an amino acid sequence as shown in SEQ ID NO.1; (b) 194th-205th amino acid residues with an amino acid sequence as shown in SEQ ID NO.2; and (c) 296th-316th amino acid residues with an amino acid sequence as shown in SEQ ID NO. 3. The bovine rotavirus fusion protein contains a plurality of epitopes, and a host can generate a plurality of antibodies after the host is immunized.

The invention discloses an avian infectious bronchitis virus (IBV)-like particle. The virus-like particle is prepared by the following steps of: transferring IBV-S, IBV-M and IBV-E genes into a baculovirus expression system respectively to obtain three recombinant rod particles; transfecting the three recombinant rod particles into insect cells respectively to obtain recombinant baculovirus rHBM-S, rHBM-M and rHBM-E; and then carrying out primary construction through a co-infection form. The virus-like particle is applied to preparation of vaccines and has a great development potential.

The invention discloses a haemonchus contortus recombinant ARF1 (ADP-ribosylation factor) protein nanometer subunit vaccine and application thereof. The haemonchus contortus nanometer material subunitvaccine is formed in a way that the recombinant ARF1 protein is coated with a PLGA (poly (lactic-co-glycolic acid)) nanometer material. The experiment utilizes the rARF1-PLGA nanometer subunit vaccine constructed by the ARF1 protein to act in the body of a mouse to induce the immune response effect of the mouse, and an experiment in the body of a goat proves that the rARF1-PLGA nanometer subunitvaccine has an immunoprotection function for an organism. The recombinant ARF1 protein is coated by the PLGA nanometer material to form the nanometer subunit vaccine so as to provide a reference for the preventive utilization of the haemonchus contortus infection of the goat.

The invention provides a flounder streptococcus dolphin GAPDH tandem multi-epitope polypeptide and its application. The provided tandem multi-epitope polypeptide is four epitope peptides connected by polypeptide linkers; wherein the four epitope peptides are The amino acid sequences are respectively SEQ ID NO: 1‑4. A specific amino acid sequence of the provided tandem multi-epitope polypeptide is SEQ ID NO:8. Another aspect of the present invention also provides a Streptococcus iniae GAPDH multi-epitope vaccine, which is prepared by using the above-mentioned tandem multi-epitope polypeptide as an antigen and a vaccine adjuvant. The multi-epitope vaccine prepared by the invention can provide strong immune protection for flounder against S. iniae infection, and the effect is obviously higher than that of GAPDH recombinant protein subunit vaccine and S. iniae inactivated vaccine.

The invention relates to the technical field for extracting vitis linn polysaccharide from grapes or raisins, and provides a method of extracting and the applications of the vitis linn polysaccharide. The extraction steps are as follow: ethanol with the concentration of 95 percent whose weight is 4 to 9 times as of grape concentrated liquid is put into the grape concentrated liquid, and then the solution is stirred fully in room temperature and keeps standing for 4 to 12 hours to precipitate crud polysaccharide which is filtered by a piece of filter cloth with 300 meshes to 500 meshes to collect the crude polysaccharide. The invention can extract the vitis linn polysaccharide effectively with simple method, the vitis linn polysaccharide can be applied to prepare drug combinations for treating diseases caused by abnormal immune functions or for regulating abnormal immune functions caused by the disease. The vitis linn polysaccharide has uniform and strong protective immune function in vivo and vitro studies, and has a good application prospect as an immunopotentiator and an immunomodulator.

An immunostimulating complex with stable and durable immune effect is prepared from hygrophilic monodas through liquid culturing, centrifugal separating of supernatant, treating it by saturated ammonium sulfate solution, suspending its deposit by PBS dialyzing to obtain toxic, concentrating, adding organic acid, adding Mega-10, treating at 37 deg.C for 4 hr, adding Quil A, cholesterol and lecithin, treating by organic acid, and dialyzing.

The invention provides chicken Eimeria tenella actin depolymerizing factor (ADF) recombinant bacillus calmette-guerin and a preparation method thereof. The preparation method comprises obtaining Eimeria tenella oocyst, extracting ribose nucleic acid (RNA), reversely transcribing the RNA into complementary deoxyribose nucleic acid (cDNA), designing primers according to an open reading frame of a cloned Eimeria tenella ADF gene sequence to perform polymerase chain reaction (PCR), enabling amplification products obtained by amplifying ADF genes to be connected with a PMD-18 vector to perform clone, performing enzyme digestion on a plasmid with correct sequencing identification, recycling a target fragment, enabling the plasmid to be respectively connected with an escherichia coli-mycobacterium shuttle expression vector PMV 261 and an integrated expression vector PMV 361 which use the same enzyme to perform enzyme reaction, and then obtaining the positive chicken Eimeria tenella recombinant bacillus calmette-guerin through resistance screening and PCR identification. The live vector vaccine is good in stability, easy to transport, store and produce, free of purification, capable of being directly used for immune protection tests, removing complex processes of post-processing of proteins and greatly reducing cost, and suitable for vast rural areas.

The invention discloses an infectious bursal disease virus strain A11 and application thereof, and belongs to the field of the microbial technology. Infectious bursal disease viruses are separated from infectious bursal disease vaccine immunity failure chicken flocks appearing in recent years, biological characteristic analysis is carried out on obtained virus isolate strains, and the infectious bursal disease virus strain A11 with good biological characteristics is screened out from the obtained virus isolate strains and is a currently-popular infectious bursal disease virus with super-strong virulence. The virulence of the virus is attenuated with a chicken embryo and cell continuous passage method to culture the low-virulence strain A11, the low-virulence strain A11 has super-strong reproductivity in cells, the virus yield in cells reaches up to 10<11> TCID50 / 0.1 ml, immune protection resisting infectious bursal disease viruses can be rapidly generated by immunizing chicks with the strain A11, immune protection can be achieved after 1 week, and the strain A11 has huge application value in developing new specific infectious bursal disease vaccines.

The present invention discloses the human interleukin-24 is shown in SEQ ID NO.1 nucleotide sequence, the sequence containing human interleukin-24 protein molecules of 601 base pairs. Human interleukin-24 recombinant plasmid pVAX1-IL-24, the building will include the use PCR IL-24cDNA from pcDNA3.1-IL-24 amplification and purification, in the purified PCR products, to really build nuclear expression vector pVAX-1, also includes recombinant plasmid pVAX1-IL-24 Construction and preparation steps. Construction of the present invention of pVAX1-IL-24 of the eukaryotic expression vector for in vivo expression in the IL-24 protein, a Th1-type cell-mediated immunity, its joint tuberculosis DNA vaccine Ag85B with immunization, than separate DNA vaccine Ag85B immune used with stronger anti-tuberculosis infection role, and enhance Ag85B resistance tuberculosis infection immune protective effect of IL-24 with that as an immune adjuvant, with the increase of anti-tuberculosis immune protection role.

Disclosed are a truncated rotavirus VP8 protein, fusion protein containing the truncated protein, conjugate containing the truncated protein, coding sequences of the truncated protein and the fusion protein and preparation methods therefor, and pharmaceutical compositions and vaccines containing the truncated protein, the fusion protein or the conjugate. The truncated protein, the fusion protein, the conjugate, the pharmaceutical compositions and the vaccines can be used for preventing, relieving or treating rotavirus infection and diseases caused by rotavirus infection, for example, rotavirus gastroenteritis and diarrhea. Also disclosed are uses of the truncated protein, the fusion protein, and the conjugate for preparing pharmaceutical compositions or vaccines.

The invention relates to the disease prevention and control technology of aquaculture animals, in particular to the attenuated strain of Streptococcus agalactiae derived from tilapia and its application. The attenuated strain of Streptococcus agalactiae derived from tilapia is YM001, which is preserved in CCTCC, and the preservation number is: CCTCC M 2014045. After the attenuated strain was activated and fermented, the 10 6 -10 9 Bacterial cells of the attenuated strain YM001 of CFU / mL are mixed with sterile phosphate buffer solution as an attenuated live vaccine for the prevention and treatment of tilapia streptococcosis, and the injection concentration is 10 5 -10 8 CFU / tail, oral administration concentration is 10 8 -10 9 CFU / tail, soaking administration concentration is 10 7 -10 8 CFU / mL. The invention relates to strain identification, virulence measurement, safety and stability of reversion, immunogenicity and immune protection effect of the attenuated strain. The tilapia streptococcal disease vaccine made with the strain has good immune protection effect and safety and strong stability.

The invention provides streptococcus iniae PDHA1 multi-epitope polypeptide. The streptococcus iniae PDHA1 multi-epitope polypeptide includes four streptococcus iniae PDHA1 protein epitope peptides which are connected through polypeptide connectors, and the amino acid sequences of the streptococcus iniae PDHA1 protein epitope peptides are respectively SEQID NO: 1-4. The invention provides a streptococcus iniae PDHA1 multi-epitope vaccine in another respect, wherein the antigen is the multi-epitope polypeptide. The prepared PDHA1 multi-epitope vaccine can provide stronger immunoprotection for paralichthys olivaceus to resist S.iniae infection, and the protection effects are obviously better than those of PDHA1 recombinant subunit vaccines and S.iniae whole bacterium inactivation vaccines.

The invention provides a multi-epitope polypeptide of flounder Streptococcus dolphin PDHA1, which comprises four Streptococcus iniae PDHA1 protein epitope peptides connected by polypeptide linkers, and the amino acid sequences of the Streptococcus iniae PDHA1 protein epitope peptides are respectively is SEQ ID NO: 1-4. Another aspect of the present invention provides a Streptococcus iniae PDHA1 multi-epitope vaccine, wherein the antigen is the above-mentioned multi-epitope polypeptide. The PDHA1 multi-epitope vaccine prepared by the invention can provide strong immune protection for flounder against S. iniae infection, and the protection effect is obviously better than PDHA1 recombinant subunit vaccine and S. iniae whole bacteria inactivated vaccine.

The invention relates to ATT fusion protein which is formed by linking 9 amino acids at Candida albicans Als3T cell epitopes before an amino acid sequence of TRAP fusion protein of staphylococcus aureus through Linker. The amino acid sequence of the fusion protein is shown in SEQ ID No.2. The invention further relates to genes for encoding the ATT fusion protein as well as a preparation method and an application of the ATT fusion protein. A mouse is immunized with the ATT fusion protein, immunodetection and a toxicity attack test are performed, and results indicate that the ATT fusion protein can induce a body to generate a stronger immune response and to have a better staphylococcus aureus infection prevention function and is an ideal candidate vaccine antigen for preventing infection of staphylococcus aureus.